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ÖZET
Amaç: Yağ dokusu, bir enerji deposu olan ana işlevinin 
yanında, bazı sitokinler salgılayarak bir endokrin organ 
olarak kabul edilir. Leptin ve rezistin, enerji homeostazi-
sinde, glikoz, lipid metabolizmasında ve vücut ağırlığının 
düzenlenmesinde önemli bir rol oynamaktadır. Bu çalış-
manın amacı, kolorektal kanserli hastalarda operasyon 
öncesi ve operasyon sonrası dönemlerde leptin ve rezis-
tin konsantrasyonlarının belirlenmesidir.
Gereç ve yöntem: Toplam 12 kolorektal kanserli hastada 
ameliyet öncesi ve sonrası dönemde ve yaş ve cinsiyet 
uyumlu 12 kişiden oluşan kontrol grubunda vücut kitle in-
deksi (VKİ) ve kan örneklerinde leptin ve rezistin düzeyleri 
ölçüldü. Serum leptin ve rezistin konsantrasyonları ELISA 
ile yöntemi ile ölçüldü.
Bulgular: Operasyon öncesi grup (leptin: 1.95±0.62 ng/
ml;  resistin  4.32±1.83  ng/ml)  kontrol  grubuna  (leptin: 
6.12±0.82 ng/ml; resistin: 10.75±1.46 ng/ml) göre karşı-
laştırıldığında leptin ve rezistin düzeylerinde azalma göz-
lemlendi (sırasıyla, p<0.001, p<0.001). Operasyon sonra-
sı grupta (3.29±0.69 ng/ml), operasyon öncesi gruba göre 
leptin düzeylerinde artış olduğu görüldü (p<0.001). Resis-
tin düzeyleri yönünden operasyon sonrası (4.75±1.33 ng/
ml) dönemle operasyon öncesi dönem arasında anlamlı 
bir farklılık yoktu (p>0.05).
Sonuç: Çalışmamızda serum leptin ve rezistin konsan-
trasyonlarının  kolorektal  kanserde  önemli  rol  oynaya-
bileceği  sonucuna  varıldı.  Ayrıca  leptinin  muhtemelen 
prognostik değeri klinikte faydalı olabilir ancak daha fazla 
araştırmanın yapılması gereklidir.
Anahtar kelimeler: Kolorektal kanser, leptin, rezistin, se-
rum
ABSTRACT
Objectives: Adipose tissue, besides its main function as 
an energy storage depot, is currently considered an en-
docrine organ that secretes several self-produced cytok-
ines. Leptin and resistin play an important role in energy 
homeostasis, glucose, lipid metabolism and regulation of 
body weight. The aim of the current study was to deter-
mine the concentration of leptin and resistin in pre-opera-
tional and post-operational periods of patients diagnosed 
as colorectal cancer.
Materials and methods: The body mass index (BMI) and 
values of leptin and resistin in blood at diagnosis were 
measured  in  12  colorectal  cancer  patients  in  pre-  and 
post-operational periods and in 12 age- and sex-matched 
controls. Serum leptin and resistin concentrations were 
measured by ELISA method. 
Results: Decreased leptin (1.95±0.62 ng/ml) and resis-
tin (4.32±1.83 ng/ml) levels were found in pre-operational 
group compared with the control group (leptin: 6.12±0.82 
ng/ml;  resistin:  10.75±1.46  ng/ml)  (p<0.001,  p<0.001, 
respectively). Leptin levels were increased in post-oper-
ational period (3.29±0.69 ng/ml) compared with the pre-
operational period (p<0.001). However, no difference was 
found in post-operative resistin levels (4.75±1.33 ng/ml) 
compared with pre-operative period (p>0.05).
Conclusion: We conclude that serum concentration of 
leptin and resistin may have a role in patients with col-
orectal cancers. Further studies are needed to investigate 
the possible prognostic value of leptin and resistin in clini-
cal practice of patients with colorectal cancers.
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INTRODUCTION
Colorectal cancer is a colon disease, which is one of 
the most frequently observed cancer types in both 
men and women. It consists 15% of all cancer cases. 
In colorectal cancer patients, tumors may exist in 
any region of colon or rectum.1
The evidence from recent studies showed that 
apart from energy storing, adipose tissue also acts 
as an endocrine organ. Both excessive and deficient 
adipose  tissue  amount  may  cause  endocrinologic 
metabolic  complications.  Preserving  the  balance 
between the levels of adipocytokines secreted from 
adipose tissue is important.2 These adipocytokines-
especially leptin and resistin are widely investigat-
ed. Because levels of these hormones alter at obesity 
and colorectal cancers usually together with cancer 
cachechcia, evaluation of adipocytokine levels may 
be important in colorectal cancer studies.3
Leptin  was  thought  to  be  expressed  and  se-
creted only by adipocytes, however their produc-
tion in placenta, gastric, colorectal and mammary 
epithelial tissue has been documented4. Leptin and 
resistin play an important role in energy homeo-
stasis, glucose, lipid metabolism and regulation of 
body weight.5,6. Recent data have also revealed the 
functions  of  adipocytokines  in  immunity,  cancer 
and bone formation2. Leptin increases the glucose 
uptake and glucose cycle in cells independent of 
insulin. Recent studies indicated that leptin is also 
associated  with  growth.7  In  vitro  cancer  studies 
demonstrated that leptin has mitogenic effects and 
increases  migration  and  growth  factors.  Another 
study showed that leptin increases the risk of colon 
cancer by affecting colon cancer cells like a growth 
factor and stimulating epithelial cell proliferation8.
Resistin  impairs  intacellular  glucose  uptake 
stimulated  by  insulin  and  increases  hepatic  glu-
cose synthesis. Serum resistin levels are elevated 
in obesity. Resistin is thought to be associated with 
inflammatory processes because it was expressed 
by human macrophages. Some studies suggest that 
elevated serum resistin levels are associated with 
increased cancer risk but there is no sufficient evi-
dence for this suggestion.9
The aim of the present study was to determine 
the concentration of leptin and resistin in pre-opera-
tional and post-operational periods of patients diag-
nosed as colorectal cancer. To our best knowledge, 
this is the first study in which resistin and leptin 
serum concentration was investigated both in pre-
operational and post-operational in colorectal can-
cer patients.
PATIENTS AND METHODS
The study comprised of three groups. First group 
was control group, second group was pre-operational 
and the third group was post-operational. The study 
population included newly diagnosed 12 adult men 
patients with colorectal cancer who were treated at 
the General Surgery Department of the Eskisehir 
Osmangazi University and control group was com-
prised of 12 men volunteers who didn’t have diabe-
tes and other chronic diseases and compatible with 
patient group in terms age and gender distribution. 
The level of body mass index (BMI) was measured 
in age- and sex-matched all groups.
The study protocol was approved by the Ethics 
Committee of the Eskisehir Osmangazi University 
and informed consent was obtained from all partici-
pants before their inclusion in the study. Exclusion 
criteria: treatment by chemotherapy, radiotherapy, 
or a major operation during the 6 months before re-
cruitment, brain metastasis, acute or chronic infec-
tion, congestive heart failure and abnormal chronic 
obstructive pulmonary disease.
Blood samples were obtained in the morning 
after  12-h  fasting  from  patients  of  all  examined 
groups and controls. Blood samples were collected 
in colorectal cancer patients at the time of diagnosis 
and at post-operational periods. Serum samples were 
obtained after 30 min clotting and centrifugation at 
1000 g for 15 min at 4°C. Serum was removed and 
stored frozen at -80°C. Fasting plasma leptin and 
resistin levels were determined in pre-operational 
and post-operational periods of patients diagnosed 
as colorectal cancer and control group. Quantitative 
parameters of serum resistin levels were measured 
by ELISA (Enzyme Linked Immunosorbent Assay) 
using AviBion Human Resistin (Orgenium Labora-
tories Division, Vantaa, FINLAND) ELISA test kits. 
Serum leptin levels were measured by ELISA (En-
zyme Linked Immunosorbent Assay) using AviBion 
Human  Leptin  (Orgenium  Laboratories  Division, 
Vantaa, FINLAND) ELISA test kits.
Statistical Analysis
Statistical analyses were performed using the SPSS 
16.0. All variables were checked for normal dis-S. Uslu et al. Serum adipocytokine levels in colorectal cancers 323
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tribution  by  Kolmogorov-Smirnov  test.  Kruskal-
Wallis was applied for multiple comparisons and 
Mann-Whitney U test for independent two samples. 
Pre- and post-operative comparisons were done by 
Wilcoxon test. Data are presented as mean ± S.D. 
Differences were considered significant at p<0.05.
RESULTS
No significant difference was found between mean 
age of two groups (Table 1). Patients had signifi-
cantly lower BMI value compared with control sub-
jects (p<0.01) (Table 1).
Our results showed decreased leptin levels in 
pre-operational group (1.95±0.62 ng/ml) compared 
control group (6.12±0.82 ng/ml) (p<0,001) (Figure 
1). The leptin levels was increased in post-opera-
tional group (3.29±0.69 ng/ml) compared in pre-
operational  group  (1.95±0.62  ng/ml)  (p<0,001). 
The resistin levels was decreased in pre-operational 
group (4.32±1.83 ng/ml) compared in control group 
(10.75±1.46  ng/ml)  (p<0.001)  and  resistin  levels 
was increased in post-operational group compared 
in pre-operational group but there was no important 
significance (p>0.05) (Figure 2). Leptin and resis-
tin levels were decreased in post-operational group 
compared  control  group  (respectively  p<0.001, 
p<0.001).
Table 1. Clinical features of patient and control groups
Controls
(n=12)
Pre-operation
(n=12)
Post-operation
(n=12)
Age (Year) 57.0 (53.0-59.0)a 60.0 (58.0-62.8) 60.0 (58.0-62.8)
BMI (kg/m2) 27.0±2.4b 21.5±2.2 21.5±2.2
BMI:  Body  mass  index;  a:  not  significant;  b:  p<0.01  (Controls  vs.  pa-
tients)
Figure 1. Serum leptin levels of patient and control 
groups
Figure 2. Serum resistin levels of patient and con-
trol groups
DISCUSSION
Adipose tissue, besides its main function as an en-
ergy storage depot, is currently considered an endo-
crine organ that secretes several self-produced cy-
tokines. These cytokines, which are named adipok-
ines, are proteins with paracrine, autocrine and en-
docrine function. The three best-studied adipokines 
are leptin, adiponectin and resistin10. Adipokines 
exert significant effects on metabolism and lipogen-
esis as well as in regulation of human inflammatory 
responses.11
Adipocytokines were shown to participate to 
some extent in the process of carcinogenesis, how-
ever  most  if  not  all  of  these  positive  data  come 
from in vitro studies on cancer cell lines. It is well 
documented that obesity increases the risk of some 
types of cancer such as that of the colon, breast and 
prostate. Multiple recent studies have indicated that 
some of adipose tissue-derived hormones may sig-
nificantly influence the growth and proliferation of 
tumorous stroma and malignant cells within.2 Leptin 
and resistin play a physiologic role in the reduction 
of food intake, energy homeostasis, and regulation 
of body weight. Leptin primarily controls body fat 
stores and have roles in promoting cellular prolif-
eration, inhibiting cellular apoptosis, and inducing 
angiogenesis.
Over the years, the association between leptin 
levels and the risk of colorectal cancer or adenoma 
has remained controversial. The expression of the 
leptin receptor in normal human colon mucosa, ad-S. Uslu et al. Serum adipocytokine levels in colorectal cancers 324
Dicle Tıp Derg / Dicle Med J Cilt / Vol 37, No 4, 321-325
enomas, and cancers suggests that a direct effect of 
leptin may be involved in carcinogenesis.12 Some 
authors suggested that low leptin serum concentra-
tion can be connected with weight loss observed in 
cachectic cancer patients.13 Simons et al. and Wal-
lace et al. suggested that low-serum leptin concen-
tration in their studies could be related to decreased 
body fat mass which is in similar to our results.14,15 
We observed, to our knowledge, for the first time, 
lower leptin concentration in patients who present-
ed newly diagnosed with colorectal cancer. We also 
found  that  highest  serum  concentration  of  leptin 
in post-operational period, than in pre-operational 
period. Based on our observations, we suspect that 
weight loss is a causative factor of hypoleptinemia 
and some unknown mechanisms may be responsi-
ble for low serum leptin levels in colorectal cancer 
patients.
The authors suspect that leptin represents the 
growth factor for colonic epithelial cells and can 
stimulate proliferation of the colon mucosa cells.16 
Garofalo et al. suggested that leptin not only stimu-
lates cell growth via ERK1/2 pathway in colorectal 
cancer but also reduces cell apoptosis.17 In our study, 
we observed significantly lower serum leptin con-
centration in colorectal cancer patients than control 
group however, higher serum leptin concentration 
in post-operational group than in pre- operational 
group.
In the present study, we observed that lowest 
resistin serum concentration in colorectal cancer pa-
tients and highest in control group. In our study, we 
found higher serum resistin concentration in post-
operational group than in control group but it did 
not observe a statistically significant difference. The 
adipocytokine resistin has been demonstrated to be 
involved in inflammatory states corresponding to its 
predominant expression in mononuclear cells, par-
ticularly in atherosclerosis.18 As for its correlation 
with cancer, two case–control studies for the risk 
of MDS or multiple myeloma have been reported.19 
Dalamaga et al. demonstrated a decreased resistin 
level in MDS patients, and speculated that it was 
due to a compensatory response to the up-regulation 
of other inflammatory factors etiologically linked to 
myelodysplasia. They also reported a decreased lev-
el of resistin in patients with multiple myeloma.20
In  other  studies,  data  also  observed  higher 
serum  resistin  concentration  in  colorectal  cancer 
group in patients than control group. These data can 
explain the highest concentration of resistin in col-
orectal cancer, which is strongly connected with in-
flammation.21 Based on our observations, we suspect 
that inflammation is not a causative factor of lower 
resistin levels and some unknown mechanisms may 
be responsible for low serum resistin in colorectal 
cancer patients. To date, the role of resistin in col-
orectal cancer is not fully elucidated yet however 
further research are necessary.
To our best knowledge, this is the first study in 
which resistin and leptin serum concentration was 
investigated both in pre-operational and post-oper-
ational in colorectal cancer patients. Based on our 
data the decrease of serum leptin and resistin con-
centrations in pre-operational period in colorectal 
cancer patients, however highest serum leptin and 
resistin  concentrations  in  post-operational  period 
in colorectal cancer patients may be dependent on 
decrease in BMI and weight loss. We conclude that 
serum concentration of leptin and resistin may play 
an important role in colorectal cancer. We also as-
sume that leptin may possibly have the prognostic 
value useful in clinical practice. Further studies are 
needed to investigate the possible prognostic value 
of leptin and resistin in clinical practice of patients 
with colorectal cancers.
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